Additional capacity broadens Grace’s fine chemical capabilities for API production
The plan is to set up an ultramodern Solvent Recovery Plant for third party purposes
The facility will manufacture Specialty and Fine Chemicals tailored to various applications across industries such as Polymer and Water Treatment facilities
PLI scheme envisages manufacturing of 41 Bulk Drugs with a total outlay of Rs. 6,940 cr. during the tenure of the scheme from 2020-21 to 2029-30
The plant will drive pharmaceutical innovation in the Northeastern India
Suven Pharmaceuticals’ API and forumulations facilities complete USFDA inspection successfully
The company is strongly committed to enhancing customer satisfaction and catering to the discerning needs of renowned pharmaceutical companies
Glenmark Life Sciences will manufacture API in the therapeutic area of urinary anti-spasmodic, to supply to the global innovator
The R&D centre is mainly dedicated to the Process R&D of New Chemical Entities (NCE) development projects
Subscribe To Our Newsletter & Stay Updated